eIF2Bδ Inhibitors are a class of chemical compounds that specifically target the δ subunit of eukaryotic initiation factor 2B (eIF2B), a critical regulator in the process of protein synthesis. eIF2B is a guanine nucleotide exchange factor (GEF) that plays a pivotal role in the initiation of translation by catalyzing the exchange of GDP for GTP on eIF2, a process essential for the formation of the translation initiation complex. The eIF2B complex is composed of five subunits (α, β, γ, δ, and ε), with each subunit contributing to the overall function and regulation of the complex. The δ subunit, in particular, is crucial for the structural stability and proper assembly of the eIF2B complex, as well as for the interaction with eIF2.
Inhibitors that target eIF2Bδ disrupt the normal function of eIF2B, leading to a decrease in its GEF activity. This disruption impacts the global regulation of protein synthesis within the cell, as the reduced activity of eIF2B results in decreased levels of active eIF2-GTP, ultimately leading to a slowdown in translation initiation. By inhibiting eIF2Bδ, researchers can investigate the broader regulatory mechanisms of protein synthesis and how cells respond to various stress conditions that affect translation. These inhibitors are valuable tools for studying the cellular responses to changes in translation rates, the role of eIF2B in maintaining proteostasis, and the intricate signaling pathways that regulate protein synthesis in response to environmental cues. Furthermore, eIF2Bδ inhibitors provide insights into the complex interplay between different subunits of the eIF2B complex and their individual contributions to the regulation of translation, making them an essential resource in the field of molecular biology and biochemistry.
Items 11 to 18 of 18 total
디스플레이 라벨:
제품명 | CAS # | 카탈로그 번호 | 수량 | 가격 | 引用 | RATING |
---|---|---|---|---|---|---|
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
독소루비신으로 인한 DNA 손상은 세포가 정상적인 기능보다 DNA 복구에 우선순위를 두게 하여 잠재적으로 RNAi 메커니즘을 억제하고 eIF2C2 수치를 감소시킬 수 있습니다. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
캠토테신과 프라임이 토포이소머라제 I을 억제하면 DNA 손상이 발생하여 RNAi 과정에 대한 집중력이 감소하고 결과적으로 eIF2C2 발현이 감소할 수 있습니다. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
겔다나마이신은 Hsp90을 억제함으로써 RNAi와 관련된 단백질을 불안정하게 만들 수 있으며, 이는 eIF2C2 안정성 또는 합성의 감소를 포함할 수 있습니다. | ||||||
MLN7243 | 1450833-55-2 | sc-507338 | 5 mg | $340.00 | ||
TAK-243은 유비퀴틴 활성화 효소(UAE)의 저분자 억제제로, 단백질 번역을 억제하여 EIF3&엡실론에 간접적으로 영향을 미칩니다. 항암 치료제로서의 가능성이 연구되고 있습니다. | ||||||
Silvestrol | 697235-38-4 | sc-507504 | 1 mg | $920.00 | ||
식물 아글레이아 포베올라타에서 분리한 천연 화합물로, EIF4AI를 강력하게 억제하는 것으로 알려져 있습니다. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $270.00 $465.00 $1607.00 $2448.00 $5239.00 | 4 | |
아글레이아 속과 같은 여러 식물에서 발견되는 또 다른 천연 화합물로 강력한 EIF4AI 억제 활성을 가지고 있습니다. | ||||||
4E1RCat | 328998-25-0 | sc-361085 sc-361085A | 10 mg 50 mg | $189.00 $797.00 | ||
eIF4F 복합체를 방해하여 캡 의존적 번역을 억제하도록 설계된 합성 EIF4AI 억제제. | ||||||
eIF4E/eIF4G Interaction Inhibitor, 4EGI-1 | 315706-13-9 | sc-202597 | 10 mg | $260.00 | 14 | |
eIF4E-eIF4G 상호 작용을 방해하여 번역 개시를 막는 저분자. |